KIRCHMEYER, Mélanie ; University of Luxembourg > Faculty of Science, Technology and Medicine > Department of Life Sciences and Medicine > Team Iris BEHRMANN
GAIGNEAUX, Anthoula ; University of Luxembourg > Faculty of Science, Technology and Medicine (FSTM) > Department of Life Sciences and Medicine (DLSM)
SERVAIS, Florence ; University of Luxembourg > Faculty of Science, Technology and Medicine > Department of Life Sciences and Medicine
Arslanow, Anita
Rubie, Claudia
Casper, Markus
Glanemann, Matthias
Martínez-Chantar, María L.
Krawczyk, Marcin
Lammert, Frank
BEHRMANN, Iris ; University of Luxembourg > Faculty of Science, Technology and Medicine (FSTM) > Department of Life Sciences and Medicine (DLSM)
External co-authors :
yes
Language :
English
Title :
Identification of Circulating MiR-4651 as Novel Biomarker for Metabolic Dysfunction–Associated Steatotic Liver Disease
Singal, A.G., Kanwal, F., Llovet, J.M., Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol 20 (2023), 864–884.
Llovet, J.M., Kelley, R.K., Villanueva, A., et al. Hepatocellular carcinoma. Nat Rev Dis Primers, 7, 2021, 6.
Harrison, S.A., Ratziu, V., Magnanensi, J., et al. NIS2+, an optimisation of the blood-based biomarker NIS4(R) technology for the detection of at-risk NASH: a prospective derivation and validation study. J Hepatol 79 (2023), 758–767.
Lopez-Riera, M., Conde, I., Tolosa, L., et al. New microRNA biomarkers for drug-induced steatosis and their potential to predict the contribution of drugs to non-alcoholic fatty liver disease. Front Pharmacol, 8, 2017, 3.
Yamamoto, Y., Kondo, S., Matsuzaki, J., et al. Highly sensitive circulating MicroRNA panel for accurate detection of hepatocellular carcinoma in patients with liver disease. Hepatol Commun 4 (2020), 284–297.
Wu, X.M., Xi, Z.F., Liao, P., et al. Diagnostic and prognostic potential of serum microRNA-4651 for patients with hepatocellular carcinoma related to aflatoxin B1. Oncotarget 8 (2017), 81235–81249.
Baselli, G.A., Dongiovanni, P., Rametta, R., et al. Liver transcriptomics highlights interleukin-32 as novel NAFLD-Related cytokine and candidate biomarker. Gut 69 (2020), 1855–1866.
Caon, E., Martins, M., Hodgetts, H., et al. Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models. J Hepatol 80 (2024), 941–956.
Ezaz, G., Trivedi, H.D., Connelly, M.A., et al. Differential associations of circulating MicroRNAs with pathogenic factors in NAFLD. Hepatol Commun 4 (2020), 670–680.
Youssef, S.S., Youness, R.A., Abbas, E.A.E., et al. miR-516a-3P, a potential circulating biomarker in hepatocellular carcinoma, correlated with rs738409 polymorphism in PNPLA3. Per Med 19 (2022), 483–493.
Donati, B., Vaira, V., Donnangelo, A., et al. A distinct miRNA expression profile in hepatocellular carcinoma arising in carriers of the I148M PNPLA3 gene variant. Dig Liver Dis, 47, 2015, e231.
Chernyak, V., Fowler, K.J., Kamaya, A., et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in At-Risk patients. Radiology 289 (2018), 816–830.
Kirchmeyer, M., Gaigneaux, A., Servais, F.A., et al. Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): impact of the PNPLA3I148M risk allele. Hepatol Commun, 7, 2023, e0306.
Margue, C., Reinsbach, S., Philippidou, D., et al. Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer?. Oncotarget 6 (2015), 12110–12127.
Kassambara, A., Rstatix: pipe-friendly framework for basic statistical tests, R Package Version 0.7.2. https://rpkgs.datanovia.com/rstatix/, 2023. (Accessed 9 March 2025)
Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stastistic Soc B 57 (1995), 289–300.
R Core Team. R: a language and environment for statistical computing, 2022, R Foundation for Statistical Computing, Vienna, Austria https://www.R-project.org.
Wickham, H., ggplot2: elegant graphics for data analysis. 2016, Springer, New York.
Wei, T., Simko, V., R package “corrplot”: visualization of a correlation matrix. vVersion 0.92. https://github.com/taiyun/corrplot, 2021. (Accessed 9 March 2025)
Khan, M., Brandenburger, T., ROCit: performance assessment of binary classifier with visualization_. R Package. Version 2.1.1. https://CRAN.R-project.org/package=ROCit, 2020. (Accessed 9 March 2025)
Kirchmeyer, M., Servais, F.A., Hamdorf, M., et al. Cytokine-mediated modulation of the hepatic miRNome: miR-146b-5p is an IL-6-inducible miRNA with multiple targets. J Leukoc Biol 104 (2018), 987–1002.
Fernandez-Tussy, P., Fernandez-Ramos, D., Lopitz-Otsoa, F., et al. miR-873-5p targets mitochondrial GNMT-complex II interface contributing to non-alcoholic fatty liver disease. Mol Metab 29 (2019), 40–54.
Fernandez-Tussy, P., Rodriguez-Agudo, R., Fernandez-Ramos, D., et al. Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. Cell Death Dis, 12, 2021, 555.
Becker, P.P., Rau, M., Schmitt, J., et al. Performance of serum microRNAs -122, -192 and -21 as biomarkers in patients with non-alcoholic steatohepatitis. PLoS One, 10, 2015, e0142661.
Xu, J., Wu, C., Che, X., et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 50 (2011), 136–142.
Pelizzaro, F., Cardin, R., Sartori, A., et al. Circulating MicroRNA-21 and MicroRNA-122 as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization. Biomedicines, 9, 2021, 890.
Sun, C., Shi, C., Duan, X., et al. Exosomal microRNA-618 derived from mesenchymal stem cells attenuate the progression of hepatic fibrosis by targeting Smad4. Bioengineered 13 (2022), 5915–5927.
Zhang, Q., Xu, M., Qu, Y., et al. Analysis of the differential expression of circulating microRNAs during the progression of hepatic fibrosis in patients with chronic hepatitis B virus infection. Mol Med Rep 12 (2015), 5647–5654.
Greco, M., Mirabelli, M., Salatino, A., et al. From euglycemia to recent onset of type 2 diabetes mellitus: a proof-of-concept study on circulating microRNA profiling reveals distinct, and early microRNA signatures. Diagnostics (Basel), 13, 2023, 2443.
Li, Y., Wang, X., Li, Z., et al. MicroRNA-4651 represses hepatocellular carcinoma cell growth and facilitates apoptosis via targeting FOXP4. Biosci Rep, 40, 2020, BSR20194011.
Zhang, T.Q., Su, Q.Q., Huang, X.Y., et al. Micro RNA-4651 serves as a potential biomarker for prognosis when selecting hepatocellular carcinoma patients for postoperative adjuvant transarterial chemoembolization therapy. Hepatol Commun 2 (2018), 1259–1273.
Elfert, A.Y., Salem, A., Abdelhamid, A.M., et al. Implication of miR-122, miR-483, and miR-335 expression levels as potential signatures in HCV-Related hepatocellular carcinoma (HCC) in Egyptian patients. Front Mol Biosci, 9, 2022, 864839.
Cui, L., Hu, Y., Bai, B., et al. Serum miR-335 level is associated with the treatment response to trans-arterial chemoembolization and prognosis in patients with hepatocellular carcinoma. Cell Physiol Biochem 37 (2015), 276–283.
Liu, M., Liu, X., Pan, M., et al. Characterization and microRNA expression analysis of serum-derived extracellular vesicles in severe liver injury from chronic HBV infection. Life (Basel), 13, 2023, 347.
Thapa, N., Chwae, Y.J., Yoo, K.H., et al. Exosomal delivery of TRAIL and miR-335 for the treatment of hepatocellular carcinoma (Review). Int J Mol Med, 51, 2023, 3.
Yang, X., Song, H., Zi, Z., et al. Circ_0005075 promotes hepatocellular carcinoma progression by suppression of microRNA-335. J Cell Physiol 234 (2019), 21937–21946.
Nie, Y., Zhu, X., Bu, N., et al. Circ_0064288 acts as an oncogene of hepatocellular carcinoma cells by inhibiting miR-335-5p expression and promoting ROCK1 expression. BMC Cancer, 22, 2022, 265.
Dohi, O., Yasui, K., Gen, Y., et al. Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Int J Oncol 42 (2013), 411–418.
Wang, F., Li, L., Piontek, K., et al. Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma. Hepatology 67 (2018), 940–954.
Zhang, N., Hu, Z., Qiang, Y., et al. Circulating miR-130b- and miR-21-based diagnostic markers and therapeutic targets for hepatocellular carcinoma. Mol Genet Genomic Med, 7, 2019, e1012.
Wu, J., Wu, Y., Luo, Y., et al. Circulating miRNA-199a and miRNA-122 levels as potential diagnostic and prognostic biomarkers for hepatocellular carcinoma. Ann Clin Lab Sci 50 (2020), 219–227.
Akuta, N., Kawamura, Y., Suzuki, F., et al. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan. Hepatol Int 10 (2016), 647–656.
Pirola, C.J., Fernandez Gianotti, T., Castano, G.O., et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 64 (2015), 800–812.
Hendy, O.M., Rabie, H., El Fouly, A., et al. The circulating Micro-RNAs (-122, -34a and -99a) as predictive biomarkers for non-alcoholic fatty liver diseases. Diabetes Metab Syndr Obes 12 (2019), 2715–2723.
Salvoza, N.C., Klinzing, D.C., Gopez-Cervantes, J., et al. Association of circulating serum miR-34a and miR-122 with dyslipidemia among patients with non-alcoholic fatty liver disease. PLoS One, 11, 2016, e0153497.
Cermelli, S., Ruggieri, A., Marrero, J.A., et al. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One, 6, 2011, e23937.
Zarrinpar, A., Gupta, S., Maurya, M.R., et al. Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study. Gut 65 (2016), 1546–1554.
Celikbilek, M., Baskol, M., Taheri, S., et al. Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J Hepatol 6 (2014), 613–620.
Auguet, T., Aragones, G., Berlanga, A., et al. miR33a/miR33b∗ and miR122 as possible contributors to hepatic lipid metabolism in Obese women with nonalcoholic fatty liver disease. Int J Mol Sci, 17, 2016, 1620.
Kim, T.H., Lee, Y., Lee, Y.S., et al. Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease. Sci Rep, 11, 2021, 14639.
Sun, C., Huang, F., Liu, X., et al. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. Int J Mol Med 35 (2015), 847–853.
Pratama, M.Y., Visintin, A., Croce, L.S., et al. Circulatory miRNA as a biomarker for therapy response and disease-free survival in hepatocellular carcinoma. Cancers (Basel), 12, 2020, 2810.
Cai, P., Mu, Y., Olveda, R.M., et al. Circulating miRNAs as footprints for liver fibrosis grading in schistosomiasis. EBioMedicine 37 (2018), 334–343.
Blaya, D., Pose, E., Coll, M., et al. Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure. JHEP Rep, 3, 2021, 100233.
Soluyanova, P., Quintas, G., Perez-Rubio, A., et al. The development of a non-invasive screening method based on serum microRNAs to quantify the percentage of liver steatosis. Biomolecules, 14, 2024, 1423.
Kurdiova, T., Balaz, M., Kovanicova, Z., et al. Serum afamin a novel marker of increased hepatic lipid content. Front Endocrinol (Lausanne), 12, 2021, 670425.
Ahn, S.B., Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: current and future developments. Clin Mol Hepatol 29 (2023), S150–S156.
